Recombinant CD19 (Tafasitamab Biosimilar) 抗体
This anti-CD19 (Tafasitamab Biosimilar) antibody is a Mammalian Cells 单克隆 antibody detecting CD19 (Tafasitamab Biosimilar) in ELISA. Suitable for 人.
产品编号 ABIN7488054
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant CD19 (Tafasitamab Biosimilar) 抗体 (ABIN7488054)
抗原
CD19 (Tafasitamab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Mammalian Cells
克隆类型
单克隆
标记
This CD19 (Tafasitamab Biosimilar) antibody is un-conjugated
应用范围
ELISA
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Tafasitamab Biosimilar - Anti-CD19 mAb
-
产品特性
- Antibody Type: IgG1-G2-kappa
-
纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
-
亚型
- IgG1
-
-
-
-
限制
- 仅限研究用
-
-
-
缓冲液
- PBS pH 7.5
-
储存条件
- -80 °C
-
储存方法
- store at -80°C
-
-
- CD19 (Tafasitamab Biosimilar)
-
物质类
- Biosimilar
-
背景
-
MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells. -
CAS-编号
- 1422527-84-1
抗原
-
You are here:
